These results highlight the differences in response to AAT and EGFR pathway-targeting treatments, which probably reflects tumor heterogeneity 22 or different subclasses of kidney tumors (clear cell (786-O) or papillary (A498) carcinomas 23). This evidence concerns the gene SERPINA1 and carcinoma.